Single-Use Bioreactor Biopharmaceuticals Company Installs 2,000L Single-Use Bioreactor

Editor: Constanze Schmitz

Rentschler Biotechnologie has put their new 2,000L single-use bioreactor into operation. The bioreactor, built and commissioned in only six months, doubles the company’s single-use manufacturing capabilities

Related Company

“The new bioreactor is already very well booked months before its commissioning which proves the high level of confidence customers have in our company,” says Frank Ternes, Chief Business Officer at Rentschler.
“The new bioreactor is already very well booked months before its commissioning which proves the high level of confidence customers have in our company,” says Frank Ternes, Chief Business Officer at Rentschler.
(Source: Rentschler Biotechnologie)

Laupheim/Germany — Rentschler Biotechnologie, a contract manufacturing and development organization (CDMO) for biopharmaceuticals, announced that their new 2,000L single-use bioreactor has been put into operation. With this new bioreactor the company joins the league of only a handful of companies having a 2,000L single-use bioreactor at their disposal, which is today’s maximum working volume in single-use.

The bioreactor, built and commissioned in only six months, doubles Rentschler’s single-use manufacturing capabilities. It seamlessly integrates in the existing manufacturing suites by supplementing two already existing 1,000L single-use bioreactors.

“The new bioreactor is already very well booked months before its commissioning which proves the high level of confidence customers have in our company,” says Frank Ternes, Chief Business Officer at Rentschler. “With this new addition to our facility we strengthen our position in single-use biomanufacturing further and get closer to our goal to manufacture phase III clinical supplies and market supplies completely in single-use.”

Rentschler has over five years’ experience with single-use bioreactors and features a facility with a completely flexible space concept and movable equipment. Single-use equipment reduces contamination risks and manufacturing costs. It permits a faster product turnaround and a shortened setup time and hence increases the capacity utilization.

Rentschler is also experiencing a high demand for stainless steel manufacturing and will invest €24m to build a Twin system with two 3,000L stainless steel bioreactors.

(ID:43279791)